What’s New

We will be regularly updating the latest biomedical literature from MEDLINE, life science journals and onlink books on our site.

June 2013

1.) Management of malignant pleural mesothelioma: have we made any progress?

Hiddinga BI, Surmont VF, Van Meerbeeck JP. Panminerva Med. 2013 Jun;55(2):157-73.

2.) A tailored, supportive care intervention using systematic assessment designed for people with inoperable lung cancer: a randomised controlled trial.

Schofield P, Ugalde A, Gough K, Reece J, Krishnasamy M, Carey M, Ball D, Aranda S. Psychooncology. 2013 Jun 4. doi: 10.1002/pon.3306.

May 2013

1.) EphB4 as a therapeutic target in mesothelioma.

Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, Gill PS, Krasnoperov V. BMC Cancer. 2013 May 30;13:269. doi: 10.1186/1471-2407-13-269.

2.) Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.

Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A. Dtsch Arztebl Int. 2013 May;110(18):319-26. doi: 10.3238/arztebl.2013.0319.

3.) Asbestos and the lung in the 21st century: an update.

Prazakova S, Thomas PS, Sandrini A, Yates DH. Clin Respir J. 2013 May 27. doi: 10.1111/crj.12028.

4.) Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database.

Farioli A, Violante FS, Mattioli S, Curti S, Kriebel D. Cancer Causes Control. 2013 May 24.

5.) Germline BAP1 Mutations Predispose to Renal Cell Carcinomas.

Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d’Enghien C, Richaudeau B, Renaudin X, Sellers J, Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal V, Sinilnikova OM, Andrieu N, Manié E, de Pauw A, Gesta P, Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, Cabaret O, Delattre O, Richard S, Caron O, Benfodda M, Hu HH, Soufir N, Bressac-de Paillerets B, Stoppa-Lyonnet D, Stern MH. Am J Hum Genet. 2013 May 14. doi:pii: S0002-9297(13)00173-0. 10.1016/j.ajhg.2013.04.012.

April 2013

1.) Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.

Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T, Nakano T. BMC Cancer. 2013 Apr 24;13(1):205.

2.) Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy?

Blum W, Schwaller B. Int J Cancer. 2013 Apr 18. doi: 10.1002/ijc.28218.

3.) The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey.

Berk S, Yalcin H, Dogan OT, Epozturk K, Akkurt I, Seyfikli Z. Environ Geochem Health. 2013 Apr 4 PMID: 23553125

4.) Current and future options for the diagnosis of malignant pleural effusion.

March 2013

1.) Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels.

2.) TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleuralmesothelioma cells through Mcl-1 and Akt protein cleavages.

Yuan BZ, Chapman J, Ding M, Wang J, Jiang B, Rojanasakul Y, Reynolds SH. BMC Cancer. 2013 Mar 22;13(1):140. PMID: 23517112

3.) Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting.

Mathur A, Blais S, Goparaju CM, Neubert T, Pass H, Levon K. PLoS One. 2013;8(3):e57681. doi: 10.1371/journal.pone.0057681. Epub 2013 Mar 13. PMID: 23516416

4.) Thoracic shaping technique to avoid residual space after extended pleurectomy/decortication.

5.) Lung volume measurements as a surrogate marker for patient response in malignant pleuralmesothelioma.

6.) Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.

Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, Marukawa K, Matsuno Y, Taguchi K, Tsujimura T. Cancer Cytopathol. 2013 Feb 28. doi: 10.1002/cncy.21269.

February 2013

1.) Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.

Habib EE, Fahmy ES. Clin Transl Oncol. 2013 Feb 14.

2.) Surgery in Mesothelioma - Where Do We Go after MARS?

Hiddinga BI, van Meerbeeck JP. J Thorac Oncol. 2013 Feb 12.

3.) New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas.

Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. Am J Pathol. 2013 Feb 7. doi:pii: S0002-9440(13)00038-2. 10.1016/j.ajpath.2012.12.028.

4.) Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies.

Ried M, Potzger T, Braune N, Diez C, Neu R, Sziklavari Z, Schalke B, Hofmann HS. J Surg Oncol. 2013 Feb 5. doi: 10.1002/jso.23321.

5.) SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.

Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. J Exp Clin Cancer Res. 2013 Feb 5;32(1):7.

6.) Health risk of chrysotile revisited.

Bernstein D, Dunnigan J, Hesterberg T, Brown R, Velasco JA, Barrera R, Hoskins J, Gibbs A. Crit Rev Toxicol. 2013 Feb;43(2):154-83. doi: 10.3109/10408444.2012.756454.

7.) Compensation for environmental asbestos-related diseases in South Africa: a neglected issue.

1.) The interaction of asbestos and iron in lung tissue revealed by synchrotron-based scanning X-ray microscopy.

Pascolo L, Gianoncelli A, Schneider G, Salomé M, Schneider M, Calligaro C, Kiskinova M, Melato M, Rizzardi C. Sci Rep. 2013;3:1123. doi: 10.1038/srep01123. Epub 2013 Jan 24.

2.) Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.

Marulli G, Di Chiara F, Braccioni F, Perissinotto E, Pasello G, Gino Favaretto A, Breda C, Rea F. Eur J Cardiothorac Surg. 2013 Jan 23

3.) CT-Guided Percutaneous Cordotomy for Intractable Pain in What is More than a Disease: Lung Malignancies.

Kanpolat Y, Ozdemir M, Al-Beyati E. Turk Neurosurg. 2013;23(1):81-7. doi: 10.5137/1019-5149.JTN.6980-12.0.

4.) Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.

Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino DT, Anna C, Adriano P, Gino C, Francesca R, Matteo C, Gbenga K, Paolo M, Francesco F. BMC Cancer. 2013 Jan 16;13(1):22.

5.) PARP11 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.

Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L. J Cell Mol Med. 2013 Jan 10. doi: 10.1111/jcmm.12000.

6.) A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.

Okonogi N, Ebara T, Ishikawa H, Yoshida D, Ueno M, Maeno T, Suga T, Nakano T. J Med Case Rep. 2012 Dec 28;6(1):427.

December 2012

1.) Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleuralmesothelioma (FAPME-1).

Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C. BMC Cancer. 2012 Dec 22;12(1):615

2.) Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: Role of inhibitor of apoptosis proteins (IAPs) and caspases.

Cregan IL, Dharmarajan AM, Fox SA. Int J Oncol. 2012 Nov 28. doi: 10.3892/ijo.2012.1715.

3.) A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.

Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J. Pathology. 2012 Dec 6.

4.) Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.

Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA. BMC Cancer. 2012 Dec 4;12(1):571.

5.) Occupational Nanosafety Considerations for Carbon Nanotubes and Carbon Nanofibers.

Castranova V, Schulte PA, Zumwalde RD. Acc Chem Res. 2012 Dec 5

6.) Mesothelioma: a soon to be forgotten disease in the United States?

Thomas D, Geck R, Rozas D, Muro-Cacho C, Rumbak M. J Bronchology Interv Pulmonol. 2012 Jul;19(3):258-61. doi: 10.1097/LBR.0b013e31825f1aba.

7.) Surgical management of malignant pleural mesothelioma.

Yanagawa J, Rusch V. Thorac Surg Clin. 2013 Feb;23(1):73-87. doi: 10.1016/j.thorsurg.2012.10.002.

November 2012

1.) Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: An in vitro evaluation.

Cameron RB, Hou D. J Thorac Cardiovasc Surg. 2012 Nov 19. doi:pii: S0022-5223(12)01348-7. 10.1016/j.jtcvs.2012.10.042

2.) Multimodal therapy of malignant pleural mesothelioma: is the replacement of radical surgery imminent?

Lindenmann J, Matzi V, Neuboeck N, Anegg U, Maier A, Smolle J, Smolle-Juettner FM. Interact Cardiovasc Thorac Surg. 2012 Nov 21.

3.) Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival

Zarogoulidis P, Mavroudi M, Porpodis K, Domvri K, Sakkas A, Machairiotis N, Stylianaki A, Tsiotsios A, Courcoutsakis N, Zarogoulidis K.

4.) Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells.

Szatmári T, Mundt F, Heidari-Hamedani G, Zong F, Ferolla E, Alexeyenko A, Hjerpe A, Dobra K. PLoS One. 2012;7(10):e48091. Epub 2012 Oct 29.

5.) Long term survival after trimodal therapy in malignant pleural mesothelioma.

Fahrner R, Ochsenbein A, Schmid RA, Carboni GL. Swiss Med Wkly. 2012 Oct 25;142:0. doi: 10.4414/smw.2012.13686.

6.) [PleurX Drainage Catheter for Palliative Treatment of Malignant Pleural Effusion].

Dilkaute M, Klapdor B, Scherff A, Ostendorf U, Ewig S. Pneumologie. 2012 Nov;66(11):637-44. doi: 10.1055/s-0032-1325881. Epub 2012 Nov 6. German.

7.) CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Amatya VJ, Takeshima Y, Aoe K, Fujimoto N, Okamoto T, Yamada T, Kishimoto T, Morimoto C, Inai K. Oncol Rep. 2012 Oct 31. doi: 10.3892/or.2012.2116

8.) The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: Possible histological transformation.

Kinoshita T, Ishii G, Matsumura Y, Shiozawa T, Aokage K, Hishida T, Yoshida J, Nagai K. Pathol Int. 2012 Nov;62(11):754-7. doi: 10.1111/pin.12003.

June 2012

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Hedy L. Kindler, Theodore G. Karrison, David R. Gandara, Charles Lu, Lee M. Krug, James P. Stevenson, Pasi A. Ja¨nne, David I. Quinn, Marianna N. Koczywas, Julie R. Brahmer, Kathy S. Albain, David A. Taber, Samuel G. Armato III, Nicholas J. Vogelzang, Helen X. Chen, Walter M. Stadler, and Everett E. Vokes. Journal of Clinical Oncology. June 4, 2012. [Epub ahead of print]

December 2011

Government and Navy knowledge regarding health hazards of asbestos: A state of the science evaluation (1900 to 1970).

Franke K, Paustenbach D. Inhal Toxicol. 2011 Dec;23 Suppl 3:1-20. PMID: 22200078 [PubMed - in process]

2.) Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma.

Nakas A, von Meyenfeldt E, Lau K, Muller S, Waller D.

November 2011

PET-CT in the diagnosis of localized malignant pleural mesothelioma

Clinical Imaging. 2011 Nov; 35(6): 476-7. Dimarakis, I., Rehman, S., Machaal, A., and Shah, R.

2.) Clinical implications of 18F- fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma

Oncology Reports. 2011 Oct 24. doi: 10.3892/or.2011.1520. Abe, Y., Tamura, K., Sakata, I., Ishida, J., Ozeki, Y., Tamura, A., Uematsu, K., Sakai, H., Goya, T., Kanazawa, M., and Machida, K.

3.) An electronic nose distinguisges exhaled breath of patients with Malignant Pleural Mesothelioma from controls

Lung Cancer. 2011 Sep 14. Dragonieri, S., van der Schee, MP, Massaro, T., Schiavulli, N., Brinkman, P., Pinca, A., Spanevello, A., Resta, O., Musti, M., and Sterk, PJ.

September 2011

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS. Cancer Immunol Immunother. 2011 Sep 13.

2.) Mesothelioma in an individual following exposure to crocidolite-containing gaskets as a teenager.

Dodson RF, Hammar SP, Poye LW. Int J Occup Environ Health. 2011 Jul-Sep;17(3):190-4.

3.) Malignant pleural mesothelioma in Singapore.

Yip CS, Koong H, Loo C, Fong K. Asian Pac J Cancer Prev. 2011;12(5):1155-9.

4.) A retrospective study of chest pain in benign asbestos pleural disease

Allen RK, Cramond T, Lennon D, Waterhouse M. Pain Med. 2011 Aug 11. doi: 10.1111/j.1526-4637.2011.01209.x.

5.) Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation

Olsen NJ, Franklin PJ, Reid A, de Klerk NH, Threlfall TJ, Shilkin K, Musk B. Med J Aust. 2011 Sep 5;195(5):271-4.

6.) Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study.

Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S. Lung Cancer. 2011 Sep 2.

July 2011

1.) Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.

Raza A, Jacobson BA, Benoit A, Patel MR, Jay-Dixon J, Hiasa H, Ferguson DM, Kratzke RA.

2.) New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization.

Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D’Urso V, Grilli B, Botta M, Giordano A, Pentimalli F

3.) Totoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding (hyperlink to this article)

Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I.

4.) Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients

Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS.

5.) The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma .

Erculj N, Kovac V, Hmeljak J, Dolzan V.

6.) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine

Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N.